Repeated mirtazapine nullifies the maintenance of previously established methamphetamine-induced conditioned place preference in rats

Behavioural Brain Research

Volumn 225, Issue 1, 2011, Pages 91-96

  Voigt, Robin M ^a,b   Mickiewicz, Amanda L ^a,b   Napier, T Celeste ^b  

^a LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

^b RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Addiction; Conditioned place preference; Methamphetamine; Mirtazapine; Psychostimulant

Indexed keywords

METHAMPHETAMINE; MIRTAZAPINE; SODIUM CHLORIDE;

ANIMAL EXPERIMENT; ANIMAL HOUSING; ARTICLE; CONDITIONING; CONTROLLED STUDY; DRUG ABUSE; MALE; MOTOR ACTIVITY; NONHUMAN; PLACE PREFERENCE; PRIORITY JOURNAL; RAT; REPEATED DRUG DOSE; SINGLE DRUG DOSE; TREATMENT DURATION; TREATMENT OUTCOME; WEIGHT GAIN;

ADRENERGIC ALPHA-ANTAGONISTS; ANALYSIS OF VARIANCE; ANIMALS; CENTRAL NERVOUS SYSTEM STIMULANTS; CONDITIONING, OPERANT; DRUG ADMINISTRATION SCHEDULE; MALE; METHAMPHETAMINE; MIANSERIN; MOTOR ACTIVITY; RATS; RATS, SPRAGUE-DAWLEY; TIME FACTORS;

EID: 79960672489     PISSN: 01664328     EISSN: 18727549     Source Type: Journal    
DOI: 10.1016/j.bbr.2011.07.009     Document Type: Article

References (69)

1. McDaid J., Graham M.P., Napier T.C. Methamphetamine-induced sensitization differentially alters pCREB and ΔFosB throughout the limbic circuit of the mammalian brain. Mol Pharmacol 2006, 70:2064-2074.
2. Zhang Y., Angulo J.A. Contrasting effects of repeated treatment vs. withdrawal of methamphetamine on tyrosine hydroxylase messenger RNA levels in the ventral tegmental area and substantia nigra zona compacta of the rat brain. Synapse 1996, 24:218-223.
3. McDaid J., Tedford C.E., Mackie A.R., Dallimore J.E., Mickiewicz A.L., Shen F., et al. Nullifying drug-induced sensitization: behavioral and electrophysiological evaluations of dopaminergic and serotonergic ligands in methamphetamine-sensitized rats. Drug Alcohol Depend 2007, 86:55-66.
4. Amano T., Matsubayashi H., Sasa M. Hypersensitivity of nucleus accumbens neurons to methamphetamine and dopamine following repeated administrations of methamphetamine. Ann NY Acad Sci 1996, 801:136-147.
5. O'Brien C.P., Childress A.R., Ehrman R., Robbins S.J. Conditioning factors in drug abuse: can they explain compulsion?. J Psychopharmacol 1998, 12:15-22.
6. Childress A.R., Mozley P.D., McElgin W., Fitzgerald J., Reivich M., O'Brien C.P. Limbic activation during cue-induced cocaine craving. Am J Psychiatry 1999, 156:11-18.
7. de Boer T.H., Nefkens F., van Helvoirt A., Van Delft A.M. Differences in modulation of noradrenergic and serotonergic transmission by the alpha-2 adrenoceptor antagonists, mirtazapine, mianserin and idazoxan. J Pharmacol Exp Ther 1996, 277:852-860.
8. de Boer T.H. The pharmacologic profile of mirtazapine. J Clin Psychiatry 1996, 57(Suppl. 4):19-25.
9. Nakayama K., Sakurai T., Katsu H. Mirtazapine increases dopamine release in prefrontal cortex by 5-HT1A receptor activation. Brain Res Bull 2004, 63:237-241.
10. Imperato A., Obinu M.C., Carta G., Mascia M.S., Casu M.A., Gessa G.L. Reduction of dopamine release and synthesis by repeated amphetamine treatment: role in behavioral sensitization. Eur J Pharmacol 1996, 317:231-237.
11. Dackis C.A., Gold M.S. New concepts in cocaine addiction: the dopamine depletion hypothesis. Neurosci Biobehav Rev 1985, 9:469-477.
12. Parsons L.H., Koob G.F., Weiss F. Serotonin dysfunction in the nucleus accumbens of rats during withdrawal after unlimited access to intravenous cocaine. J Pharmacol Exp Ther 1995, 274:1182-1191.
13. Orejarena M.J., Berrendero F., Maldonado R., Robledo P. Differential changes in mesolimbic dopamine following contingent and non-contingent MDMA self-administration in mice. Psychopharmacology (Berl) 2009, 205:457-466.
14. Rothman R.B., Blough B.E., Baumann M.H. Dual dopamine/serotonin releasers as potential medications for stimulant and alcohol addictions. AAPS J 2007, 9:E1-E10.
15. Herrold A.A., Shen F., Graham M.P., Harper L.K., Specio S.E., Tedford C.E., et al. Mirtazapine treatment after conditioning with methamphetamine alters subsequent expression of place preference. Drug Alcohol Depend 2009, 99:231-239.
16. Brabant C., Quertemont E., Tirelli E. Influence of the dose and the number of drug-context pairings on the magnitude and the long-lasting retention of cocaine-induced conditioned place preference in C57BL/6J mice. Psychopharmacology (Berl) 2005, 180:33-40.
17. Landgrebe J., Welzl G., Metz T., van Gaalen M.M., Ropers H., Wurst W., et al. Molecular characterisation of antidepressant effects in the mouse brain using gene expression profiling. J Psychiatr Res 2002, 36:119-129.
18. Haddjeri N., Blier P., De Montigny C. Acute and long-term actions of the antidepressant drug mirtazapine on central 5-HT neurotransmission. J Affect Disord 1998, 51:255-266.
19. Haddjeri N., Blier P., De Montigny C. Long-term antidepressant treatments result in a tonic activation of forebrain 5-HT1A receptors. J Neurosci 1998, 18:10150-10156.
20. Haddjeri N., Blier P., de M.C. Noradrenergic modulation of central serotonergic neurotransmission: acute and long-term actions of mirtazapine. Int Clin Psychopharmacol 1995, 10(Suppl. 4):11-17.
21. Shen F., Meredith G.E., Napier T.C. Amphetamine-induced place preference and conditioned motor sensitization requires activation of tyrosine kinase receptors in the hippocampus. J Neurosci 2006, 26:11041-11051.
22. Rademacher D.J., Kovacs B., Shen F., Napier T.C., Meredith G.E. The neural substrates of amphetamine conditioned place preference: implications for the formation of conditioned stimulus-reward associations. Eur J Neurosci 2006, 24:2089-2097.
23. Voigt R.M., Napier T.C. Systemic baclofen blocks the expression of methamphetamine-induced conditioned place preference: implications for GABAB receptors in the medial dorsal thalamus. Soc Neurosci Abstr 2007, 916.16.
24. Voigt R.M., Harper L.K., Napier T.C. The ability of mirtazapine to inhibit the expression of methamphetamine-induced conditioned place preference is context independent. Soc Neurosci Abstr 2006, 753.10.
25. Sandker G.W., Vos R.M., Delbressine L.P., Slooff M.J., Meijer D.K., Groothuis G.M. Metabolism of three pharmacologically active drugs in isolated human and rat hepatocytes: analysis of interspecies variability and comparison with metabolism in vivo. Xenobiotica 1994, 24:143-155.
26. Timmer C.J., Sitsen J.M., Delbressine L.P. Clinical pharmacokinetics of mirtazapine. Clin Pharmacokinet 2000, 38:461-474.
27. Fava M. Weight gain and antidepressants. J Clin Psychiatry 2000, 61(Suppl. 11):37-41.
28. Kraus T., Haack M., Schuld A., Hinze-Selch D., Koethe D., Pollmacher T. Body weight, the tumor necrosis factor system, and leptin production during treatment with mirtazapine or venlafaxine. Pharmacopsychiatry 2002, 35:220-225.
29. Masand P.S., Gupta S. Long-term side effects of newer-generation antidepressants: SSRIS venlafaxine, nefazodone, bupropion, and mirtazapine,. Ann Clin Psychiatry 2002, 14:175-182.
30. Yuferov V., Nielsen D., Butelman E., Kreek M.J. Microarray studies of psychostimulant-induced changes in gene expression. Addict Biol 2005, 10:101-118.
31. Napier T.C., Istre E.D. Methamphetamine-induced sensitization includes a functional upregulation of ventral pallidal 5-HT2A/2C receptors. Synapse 2008, 62:14-21.
32. Bamford N.S., Zhang H., Joyce J.A., Scarlis C.A., Hanan W., Wu N.P., et al. Repeated exposure to methamphetamine causes long-lasting presynaptic corticostriatal depression that is renormalized with drug readministration. Neuron 2008, 58:89-103.
33. Faure J.J., Hattingh S.M., Stein D.J., Daniels W.M. Proteomic analysis reveals differentially expressed proteins in the rat frontal cortex after methamphetamine treatment. Metab Brain Dis 2009, 24:685-700.
34. McGaugh J.L. Memory-a century of consolidation. Science 2000, 287:248-251.
35. Wang H., Hu Y., Tsien J.Z. Molecular and systems mechanisms of memory consolidation and storage. Prog Neurobiol 2006, 79:123-135.
36. Alberini C.M., Milekic M.H., Tronel S. Mechanisms of memory stabilization and de-stabilization. Cell Mol Life Sci 2006, 63:999-1008.
37. Bailey C.H., Kandel E.R., Si K. The persistence of long-term memory: a molecular approach to self-sustaining changes in learning-induced synaptic growth. Neuron 2004, 44:49-57.
38. Micheau J., Riedel G. Protein kinases: which one is the memory molecule?. Cell Mol Life Sci 1999, 55:534-548.
39. Izquierdo I., Barros D.M., Mello e Souza, de Souza M.M., Izquierdo L.A., Medina J.H. Mechanisms for memory types differ. Nature 1998, 393:635-636.
40. McGaugh J.L. Time-dependent processes in memory storage. Science 1966, 153:1351-1358.
41. Nowakowska E., Chodera A., Kus K. Behavioral and memory improving effects of mirtazapine in rats. Pol J Pharmacol 1999, 51:463-469.
42. Huzarska M., Zielinski M., Herman Z.S. Repeated treatment with antidepressants enhances dopamine D1 receptor gene expression in the rat brain. Eur J Pharmacol 2006, 532:208-213.
43. Rogoz Z., Skuza G., Legutko B. Repeated treatment with mirtazepine induces brain-derived neurotrophic factor gene expression in rats. J Physiol Pharmacol 2005, 56:661-671.
44. De Boer T. The effects of mirtazapine on central noradrenergic and serotonergic neurotransmission. Int Clin Psychopharmacol 1995, 10(Suppl. 4):19-23.
45. Haddjeri N., Blier P., de M.C. Effect of the alpha-2 adrenoceptor antagonist mirtazapine on the 5-hydroxytryptamine system in the rat brain. J Pharmacol Exp Ther 1996, 277:861-871.
46. McGrath C., Burrows G.D., Norman T.R. Neurochemical effects of the enantiomers of mirtazapine in normal rats. Eur J Pharmacol 1998, 356:121-126.
47. Kubota Y., Ito C., Sakurai E., Sakurai E., Watanabe T., Ohtsu H. Increased methamphetamine-induced locomotor activity and behavioral sensitization in histamine-deficient mice. J Neurochem 2002, 83:837-845.
48. Fletcher P.J., Grottick A.J., Higgins G.A. Differential effects of the 5-HT(2A) receptor antagonist M100,907 and the 5-HT(2C) receptor antagonist SB242,084 on cocaine-induced locomotor activity, cocaine self-administration and cocaine-induced reinstatement of responding. Neuropschopharmacology 2002, 27:576-586.
49. Rocha B.A., Goulding E.H., O'Dell L.E., Mead A.N., Coufal N.G., Parsons L.H., et al. Enhanced locomotor, reinforcing, and neurochemical effects of cocaine in serotonin 5-hydroxytryptamine 2C receptor mutant mice. J Neurosci 2002, 22:10039-10045.
50. Feltenstein M.W., See R.E. Potentiation of cue-induced reinstatement of cocaine-seeking in rats by the anxiogenic drug yohimbine. Behav Brain Res 2006, 174:1-8.
51. Shepard J.D., Bossert J.M., Liu S.Y., Shaham Y. The anxiogenic drug yohimbine reinstates methamphetamine seeking in a rat model of drug relapse. Biol Psychiatry 2004, 55:1082-1089.
52. Ito C., Onodera K., Watanabe T., Sato M. Effects of histamine agents on methamphetamine-induced stereotyped behavior and behavioral sensitization in rats. Psychopharmacology (Berl) 1997, 130:362-367.
53. Ago Y., Nakamura S., Kajita N., Uda M., Hashimoto H., Baba A., et al. Ritanserin reverses repeated methamphetamine-induced behavioral and neurochemical sensitization in mice. Synapse 2007, 61:757-763.
54. McMahon L.R., Cunningham K.A. Antagonism of 5-hydroxytryptamine(2a) receptors attenuates the behavioral effects of cocaine in rats. J Pharmacol Exp Ther 2001, 297:357-363.
55. Carey R.J., DePalma G., Damianopoulos E., Shanahan A., Muller C.P., Huston J.P. Evidence that the 5-HT1A autoreceptor is an important pharmacological target for the modulation of cocaine behavioral stimulant effects. Brain Res 2005, 1034:162-171.
56. Ago Y., Nakamura S., Uda M., Kajii Y., Abe M., Baba A., et al. Attenuation by the 5-HT1A receptor agonist osemozotan of the behavioral effects of single and repeated methamphetamine in mice. Neuropharmacology 2006, 51:914-922.
57. Peltier R., Schenk S. Effects of serotonergic manipulations on cocaine self-administration in rats. Psychopharmacology (Berl) 1993, 110:390-394.
58. Meil W.M., Schechter M.D. Olanzapine attenuates the reinforcing effects of cocaine. Eur J Pharmacol 1997, 340:17-26.
59. Nic Dhonnchadha B.A., Fox R.G., Stutz S.J., Rice K.C., Cunningham K.A. Blockade of the serotonin 5-ht2a receptor suppresses cue-evoked reinstatement of cocaine-seeking behavior in a rat self-administration model. Behav Neurosci 2009, 123:382-396.
60. Pitsikas N., Tsitsirigou S., Zisopoulou S., Sakellaridis N. The 5-HT1A receptor and recognition memory. Possible modulation of its behavioral effects by the nitrergic system. Behav Brain Res 2005, 159:287-293.
61. Egashira N., Yano A., Ishigami N., Mishima K., Iwasaki K., Fujioka M., et al. Investigation of mechanisms mediating 8-OH-DPAT-induced impairment of spatial memory: involvement of 5-HT1A receptors in the dorsal hippocampus in rats. Brain Res 2006, 1069:54-62.
62. Liang K.C. Pre- or post-training injection of buspirone impaired retention in the inhibitory avoidance task: involvement of amygdala 5-HT1A receptors. Eur J Neurosci 1999, 11:1491-1500.
63. Rothman R.B., Blough B.E., Baumann M.H. Dual dopamine/serotonin releasers: potential treatment agents for stimulant addiction. Exp Clin Psychopharmacol 2008, 16:458-474.
64. Rothman R.B., Blough B.E., Baumann M.H. Dopamine/serotonin releasers as medications for stimulant addictions. Prog Brain Res 2008, 172:385-406.
65. Kongsakon R., Papadopoulos K.I., Saguansiritham R. Mirtazapine in amphetamine detoxification: a placebo-controlled pilot study. Int Clin Psychopharmacol 2005, 20:253-256.
66. McGregor C., Srisurapanont M., Mitchell A., Wickes W., White J.M. Symptoms and sleep patterns during inpatient treatment of methamphetamine withdrawal: a comparison of mirtazapine and modafinil with treatment as usual. J Subst Abuse Treat 2008, 35:334-342.
67. Rose M.E., Grant J.E. Pharmacotherapy for methamphetamine dependence: a review of the pathophysiology of methamphetamine addiction and the theoretical basis and efficacy of pharmacotherapeutic interventions. Ann Clin Psychiatry 2008, 20:145-155.
68. Cruickshank C.C., Montebello M.E., Dyer K.R., Quigley A., Blaszczyk J., Tomkins S., et al. A placebo-controlled trial of mirtazapine for the management of methamphetamine withdrawal. Drug Alcohol Rev 2008, 27:326-333.
69. Shoptaw S.J., Kao U., Heinzerling K., Ling W. Treatment for amphetamine withdrawal. Cochrane Database Syst Rev 2009, CD003021.